Replimune Group, Inc. — Form 8-K Summary
Business context and reporting period
Replimune Group, Inc. filed a Current Report on Form 8-K concerning a board departure. The earliest reported event occurred on July 14, 2023; the filing was signed and furnished with a related press release dated July 20, 2023. The filing does not provide quarterly or annual financial results.
Financial and operating metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Material changes
- Sander Slootweg notified the Board on July 14, 2023 that he would not stand for reelection at the 2023 annual meeting of stockholders.
- His service as a director will end at the conclusion of the annual meeting.
- The company stated that his decision was not due to any dispute or disagreement with the company, management, the Board, or the company’s operations, policies, or practices.
Guidance, outlook, risks, and unusual items
No financial guidance, business outlook, contingencies, or material operating risks were disclosed. The principal governance item is the planned change in Board membership. Exhibit 99.1 is a related news release dated July 20, 2023.
Important facts to verify
- Confirm the outcome and effective date of Mr. Slootweg’s departure following the 2023 annual meeting.
- Review the related July 20, 2023 news release furnished as Exhibit 99.1.
- Use the company’s periodic reports for current financial performance, cash runway, debt, liquidity, and clinical-program updates, which are not included in this filing.